TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02932917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MapMySmoke
Description: Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
Study: NCT01705002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV
Study: NCT02292342

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Epicatechin 0.5 mg/kg
Description: EC 0.5

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin 0.5 mg/kg
Description: EC 0.5

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin 0.5 mg/kg
Description: EC 0.5

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin 0.5 mg/kg
Description: EC 0.5

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Epicatechin 1.0 mg/kg
Description: EC 1.0

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin 1.0 mg/kg
Description: EC 1.0

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin 1.0 mg/kg
Description: EC 1.0

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin 1.0 mg/kg
Description: EC 1.0
Study: NCT04162600

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG
Description: Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Rabies Vaccine
Description: A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG
Description: Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG
Description: Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Rabies Vaccine
Description: A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Rabies Vaccine
Description: A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
Study: NCT01872897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Alginate Double Action Tablets
Description: Four tablets as a single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets as a single dose
Study: NCT00485433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl given during hernia repair

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: SKY0402 given during hernia repair

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: SKY0402 given during hernia repair

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: SKY0402 given during hernia repair
Study: NCT04472923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training.~Biofeedback was planned after full guardians' education. Local hygiene for perianal skin for soiling episodes and using zinc oxide cream to prevent excoriation. Biofeedback was done using two types of catheters; a 24-channel water-perfused catheter with latex balloon for sensory training and a double-lumen rectal PVC balloon clothed catheter (MMS U-72210) for strength training. Each biofeedback session took 30 minutes with two sessions per week for 3 months.
Study: NCT05547763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates
Description: under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates
Description: under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.
Study: NCT02371759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L+C maxillary anesthesia
Description: Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L+C maxillary anesthesia
Description: Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L+C mandibular anesthesia
Description: Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L+C mandibular anesthesia
Description: Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L+E maxillary anesthesia
Description: Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L+E maxillary anesthesia
Description: Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L+E mandibular anesthesia
Description: Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
Study: NCT02746900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Description: McDonald cervical cerclage
Study: NCT01345292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthwash
Description: Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate toothpaste
Description: Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium fluoride toothpaste
Description: Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
Study: NCT02525705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Glucose
Description: 1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
Study: NCT01879904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Description: This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
Study: NCT02161510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2248
Description: MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2248
Description: MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2248
Description: MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2248
Description: MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2248
Description: MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
Study: NCT02371759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L+E mandibular anesthesia
Description: Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
Study: NCT02995343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypogastric and/or uterine artery ligation
Study: NCT03695432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flubio
Description: Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lacidofil
Description: Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo probiotic
Description: Capsul
Study: NCT01896037

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 supplements
Description: Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
Study: NCT03556605

Intervention type: OTHER
Group type: OTHER
Intervention: OneTouch Reveal® Mobile APP system
Description: Improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitor and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).

Intervention type: OTHER
Group type: OTHER
Intervention: Current Blood Glucose Monitor
Description: Subjects continue to use current Blood Glucose Monitor without connection to mobile diabetes apps.
Study: NCT01705002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: 2 mg/kg dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
Study: NCT00030407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
Study: NCT05685017

Intervention type: DIAGNOSTIC_TEST
Intervention: Nur Aisiyah Widjaja
Description: Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation
Study: NCT02091349

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: polydextrose
Description: polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polydextrose
Description: polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polydextrose
Description: polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: soluble corn fiber
Description: nutirose- 7, 14, or 21 grams/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soluble corn fiber
Description: nutirose- 7, 14, or 21 grams/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soluble corn fiber
Description: nutirose- 7, 14, or 21 grams/day
Study: NCT03147833

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sport beverages Protein
Description: Beverage ingested before each night sleep during the intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sport beverages Carbohydrate
Description: Beverage ingested before each night sleep during the intervention
Study: NCT00876356

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated Linoleic Acid (CLA)
Description: CLA 4.5g/day in three divided doses p.o. for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Olive oil 4.5g/day x 12 weeks
Study: NCT02609516

Intervention type: OTHER
Intervention: This is not an intervention study
Description: This study is based on the retrospective analysis of linked electronic health records.

Intervention type: OTHER
Intervention: This is not an intervention study
Description: This study is based on the retrospective analysis of linked electronic health records.
Study: NCT02653729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behaviour therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Espidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Espidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olepra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olepra

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donu

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donu
Study: NCT01074905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: 2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: 25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine/Primaquine
Description: Chloroquine 3 days and Primaquine 14 days
Study: NCT02414659

Intervention type: PROCEDURE
Intervention: Umbilical cord blood collection, in-utero
Description: Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
Study: NCT03911713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: VX-561 tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: VX-561 tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: VX-561 tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: VX-561 tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: 150-mg film-coated tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to IVA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to IVA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to IVA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to IVA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebos matched to VX-561.
Study: NCT02641132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C 0.02%
Description: Pterygium excision with application of mitomycin C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C 0.02%
Description: Pterygium excision with application of mitomycin C

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterygium surgery
Description: Two different procedures- excision of the head and the body and excision of the head only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pterygium surgery
Description: Two different procedures- excision of the head and the body and excision of the head only
Study: NCT03265665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTION Intervention
Description: The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive lifestyle physical activity intervention for African American (AA) women. There are 2 phases to the intervention: Adoptive (24 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. 1 Group session (maintenance): watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking, reinforce barriers and facilitators to walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced usual care
Description: Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.~Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.
Study: NCT02457481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embryo Culture medium
Description: Two step sequential embryo culture medium system
Study: NCT03758339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: Single dose of 300 mg of \[¹⁴C\]-tucatinib containing approximately 150 μCi of \[¹⁴C\] radioactivity
Study: NCT02828930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]-radiolabeled Idasanutlin
Description: \[13C\]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-radiolabeled Idasanutlin
Description: \[14C\]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
Study: NCT03956134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Test Product 1
Description: Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Test Product 1
Description: Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Test Product 2
Description: Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Test Product 2
Description: Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol Prolonged-release Reference Product
Description: Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
Study: NCT03820180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: 2 inhalations of Test and Reference product in each study period